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32131
Updating the relative risk of ultraviolet exposure and melanoma
in fair skin types: A systematic review
Manisha Ravi, BS, The Ohio State University College of Medicine;
Michael Kwa, MD, Department of Dermatology, Henry Ford Health
System; Kriti Babu, BS, Wayne State University School of Medicine; Henry W. Lim,
MD, Department of Dermatology, Henry Ford Health System
In 2005, a meta-analysis found that varying types of UV exposure contributed to an
increased relative risk of melanoma. Recently, a 2021 review failed to establish a
similar link in individuals with skin of color. Within the last 2 decades, no studies
have comprehensively reviewed the risk of varying types of UV exposure on
melanoma in fair skin. Thus, we performed a systematic review from 2002-2021
analyzing UV exposure and melanoma risk in Fitzpatrick type I-IV individuals. Out of
12,263 studies, 26 met inclusion criteria. A majority showed an association with UV
index (6/9), left-sided laterality (1/1), sunburn history (11/13), and outdoor leisure
activity (3/3). UV index studies were all ecological and presented primarily positive
correlations. For sunburn history, studies encompassed 2309 melanomas, and
significant odds ratios (OR) ranged from 1.69 (1.00-2.98) to 8.48 (4.35-16.54) with
higher odds ratios for increasing numbers of sunburns. For outdoor leisure
correlating with prior definitions of intermittent sun exposure, studies encompassed 514 melanomas, and ORs ranged from 2.70 (1.04-6.80) to 4.18 (1.83-9.93). A
positive association was found in 2 (n ¼ 2/6) studies for cumulative or annual sun
exposure, 2 (n ¼ 2/5) studies with occupational sun exposure, 2 (n ¼ 2/4) studies
with sun vacations, and 0 (n ¼ 0/2) studies with latitude. This study highlights the
significant relationships between specific types of UV exposure and melanoma at
higher rates than previously summarized due to an emphasis on fair skin types.
Critically, there remains high heterogeneity in how UV exposure is captured that
may contribute to mixed results.
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Utilization and trends of dupilumab prescriptions among Medicare Part D patients: 2017-2019
Rahul Raiker, BS, West Virginia University School of Medicine; Haig
Pakhchanian, BS, George Washington University School of Medicine
and Health Sciences; Melanie Wolf, DO, OhioHealth Riverside Methodist
Hospital; Shannon Trotter, DO, OhioHealth Riverside Methodist Hospital
Background: Dupilumab is a monoclonal antibody antagonist of the interleukin 4 (IL4) receptor alpha and was approved for the treatment of moderate-to-severe atopic
dermatitis in 2017. Little data exist on the national prescribing patterns of
dupilumab and the goal of this study was to assess these patterns.
Design: A retrospective analysis was conducted using the Medicare Part D Prescriber
datasets from 2017-2019. Data from dupilumab prescriptions made by any type of
healthcare provider were analyzed. Yearly claims per 100,000 beneficiaries, total
drug costs, and total drug supply days were recorded. Average annual growth rate
(AAGR) was calculated.
Summary: From 2017-2019, the number of dupilumab prescribers who made $11
claims to Medicare Part D enrollees increased by 416%. The majority of the
prescribers were dermatologists, followed by advanced practice providers and
allergists. The highest proportion of claims and beneficiaries receiving dupilumab
each year were those [65 years of age and located in the South. AAGR increased for
yearly claims per 100,000 beneficiaries (AAGR ¼ 200%), total drug costs (AAGR ¼
216%), and total drug supply days (AAGR ¼ 396%).
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Utilization and trends of select FDA indicated cutaneous T-cell
lymphoma prescriptions among Medicare Part D patients: 20132019
Rahul Raiker, BS, West Virginia University School of Medicine; Haig
Pakhchanian, BS, George Washington University School of Medicine and Health
Sciences; Melanie Wolf, DO, OhioHealth Riverside Methodist, OhioHealth
Riverside Methodist
Background: Cutaneous T-cell lymphoma (CTCL) is an indolent malignancy of T-cells
with various cutaneous presentations. Limited data exist on national prescription
patterns for select FDA indicated drugs such as mechlorethamine, bexarotene,
vorinostat and romidepsin. The goal of this study was to assess these patterns.
Design: A retrospective analysis was conducted using the Medicare Part D Prescriber
datasets from 2013-2019. Mechlorethamine, bexarotene, vorinostat and romidepsin
data were extracted. Yearly claims per 100,000 beneficiaries, total drug costs, and
total prescribers were recorded. Average annual growth rate (AAGR) was calculated
and trend significance was determined through a linear regression model.
Summary: From 2013-2019, AAGR for claims per 100k beneficiaries increased for
mechlorethamine (99%) and romidepsin (11.5%), but decreased for bexarotene
(-1.3%) and vorinostat (-16.4%). However, no statistically significant increased or
decreased trend was seen for total drug costs or total prescribers for any of the
assessed CTCL drugs.
Conclusion: Mechlorethamine and romidepsin claims increased while bexarotene
and vorinostat claims decreased over the years. Total costs and prescribers have
remained stable with no significant trend for all examined drugs. Future studies are
warranted to assess whether these drugs may lose preference over newer CTCL
drugs such as brentuximab vedotin or mogamulizumab as more data becomes
available.
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Utilization of a cutaneous lymphoma primer to improve resident
education
Madelyn Jeter, MD, Department of Dermatology, Saint Louis University
School of Medicine; Eamonn Maher, MD, Department of Dermatology,
New York University Grossman School of Medicine
Background: Cutaneous lymphoma (CL) is a somewhat esoteric subject from the
vantage point of the general dermatologist, however, rarity of a diagnosis is not an
adequate reason to discount the benefit in learning more about this subject,
particularly in residency. There is a lack of access to concise, relevantly organized
educational materials pertaining to CL at the resident level. Furthermore, no data has
been published regarding dermatology resident comfort level with diagnosis and
treatment of CL. This study aims to improve resident understanding through the
creation of a CL primer.
Methods: A pre-test evaluated resident comfort level in understanding normal lymph
node (LN) architecture and staining and recognizing clinical and histologic features
of CL using a 10-point Likert scale (1 being not at all comfortable, 10 being very
comfortable). The pre-test was administered to eleven Saint Louis University
dermatology residents, followed by dissemination of an online CL primer. After
reviewing the primer, a post-test assessing the same parameters was distributed, and
post-test results were compared with pre-test scores.
Results: Residents showed a significant improvement in their comfort level in
understanding normal LN structure and CL, clinically and histologically after
reviewing the CL primer. The mean comfort level score improved from 4.66 (95%
Cl [3.88-5.44]) to 7.69 (95% Cl [7.43-7.95]), with a mean difference of 3.03 (95% Cl
[2.24 e 3.81]) (P \.0001).

Conclusion: The prescribing trends of dupilumab continues to grow significantly
across all providers in claims made per 100k beneficiaries, total drug costs, and total
drug supply days. These findings demonstrate the increasing access to dupilumab,
and as other indications receive approval, additional studies will be needed to assess
whether this trajectory continues.

Conclusion: Use of a CL primer improved resident understanding of normal LN
architecture and staining patterns, and with recognition of clinical and histologic
features of CL.
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